None
Quote | Constellation Pharmaceuticals Inc. (NASDAQ:CNST)
Last: | $33.99 |
---|---|
Change Percent: | 0.06% |
Open: | $33.98 |
Close: | $33.99 |
High: | $34.05 |
Low: | $33.97 |
Volume: | 1,283,908 |
Last Trade Date Time: | 07/14/2021 04:42:26 am |
News | Constellation Pharmaceuticals Inc. (NASDAQ:CNST)
The biotechnology sector largely underperformed the broader market this year, particularly small- to mid-cap biotech indexes whose constituents tend to experience more volatility. Contributing factors to the market decline include fears of increased regulation and oversight of M&A...
M&A activity increases with eight new deals announced. Welbilt terminates its deal with The Middleby Corporation and agrees to be acquired by Ali Group. Monmouth Real Estate Investment Corporation receives an unsolicited acquisition proposal from a large private investment fir...
Message Board Posts | Constellation Pharmaceuticals Inc. (NASDAQ:CNST)
Subject | By | Source | When |
---|---|---|---|
znewcar1: CNST 34% v3,5M c30.36 f47,5M H31.29 S28 | znewcar1 | investorshangout | 12/08/2020 12:23:40 AM |
znewcar1: CNST 90% v8,1M c28.10 f25M H45.42 looking for support big vol | znewcar1 | investorshangout | 11/06/2019 9:08:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Constellation Pharmaceuticals Inc. Company Name:
CNST Stock Symbol:
NASDAQ Market:
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...